ESCRS 2023: Krysten Williams talks about bringing Heidelberg image quality into the surgical theater

News
Video

At the 2023 European Society Of Cataract & Refractive Surgeons (ESCRS) meeting in Vienna, Krysten Williams, head of marketing and education at Heidelberg Engineering, spoke to our team about the newest imaging advancements in the clinic and the operating room.

Ophthalmology Times Europe is covering this year's European Society Of Cataract & Refractive Surgeons (ESCRS) meeting in Vienna, Austria. We caught up with Krysten Williams, head of marketing and education at Heidelberg Engineering, who spoke to our team about the newest imaging advancements in the clinic and the operating room.

Transcript

Editor's note: This transcript has been edited for clarity.

Krysten Williams: Hi, my name is Krysten Williams and I'm head of marketing and education at Heidelberg Engineering. So our theme for the ESCRS this year is "Heidelberg Engineering Image Quality." And it's really important because we started in the posterior segment, and we're known for our retinal images. But in recent years, we've moved into the anterior segment space. And this year, what we're showing is that we're bringing Heidelberg image quality into the surgical theater.

We are collaborating with Bausch + Lomb along with the SeeLuma™ microscope. And here at the ESCRS, we're very excited to show the integrated OCT into the SeeLuma™ platform. The fact that we're moving into the surgical space is surprising because for many years, we've been known as a diagnostic image – imaging company.

Now for the first time, we're bringing OCT images and the power of the diagnostic capability into the surgical space and doctors can actually have this information at their fingertips right in the surgical theater, because we are we've gone from posterior to anterior, and from the diagnostic clinic into the surgical theater. We have a complete ecosystem that integrates our products and gives us that complete continuum between clinic and the OR.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.